Company news

Niagen Bioscience, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

ChromaDex Wins International 2022 European NutraIngredients Award for Developing the Science Behind Niagen®

May 16, 2022

ChromaDex Corporation Reports First Quarter 2022 Financial Results

May 11, 2022

ChromaDex to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

April 28, 2022

ChromaDex Appoints Ann Cohen and Kristin Patrick to its Board of Directors

April 21, 2022

ChromaDex Announces Issuance of Additional New U.S. Continuation Patent, Further Protecting Future Innovations

March 15, 2022

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2021 Results

March 8, 2022

ChromaDex Shares Findings from First-Ever Peer-Reviewed Published Clinical Study Analyzing the Promising Effect of Nicotinamide Riboside (NR) Supplementation in Patients with Parkinson’s Disease (PD)

March 1, 2022

ChromaDex Announces Issuance of New U.S. Continuation Patent, Expanding Intellectual Property Portfolio for Nicotinamide Riboside

February 8, 2022

ChromaDex External Research Program (CERP™) Celebrates 100 Peer-Reviewed Published Studies on Niagen® and Other Ingredients

January 30, 2022

ChromaDex Announces Results of New Pilot Clinical Trial Showing Anti-Inflammatory Effects of Nicotinamide Riboside (NR) Supplementation

January 24, 2022

ChromaDex and Designs for Health Partner for New Product Development on Niagen®

January 19, 2022

ChromaDex Corporation Reports Third Quarter 2021 Financial Results

November 2, 2021

ChromaDex to Report Third Quarter 2021 Financial Results on Wednesday, Nov. 3, 2021

October 12, 2021

ChromaDex Comments on Jury Award Against Elysium Health and Reiterates Plans for Growth

September 30, 2021

ChromaDex Partners with Sinopharm Xingsha for Cross-Border Sales of Tru Niagen® into Mainland China

September 28, 2021

ChromaDex Shares Preclinical Research Findings and Scientific Initiations from the ChromaDex External Research Program (CERP™)

September 19, 2021

ChromaDex Corporation Reports Second Quarter 2021 Financial Results

August 2, 2021

ChromaDex to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021

July 19, 2021

ChromaDex and Walmart Launch Tru Niagen® in 3,800 Walmart Stores Across the United States

June 6, 2021

ChromaDex and Ro Partner for New Product Development

May 3, 2021

ChromaDex to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021

April 28, 2021

ChromaDex and Health & Happiness (H&H) Group Announce Supply Agreement for Niagen®

April 27, 2021

ChromaDex Appoints Fadi Karam as Chief Marketing Officer

April 18, 2021

ChromaDex to Present at the Lytham Partners Spring 2021 Investor Conference

March 23, 2021

ChromaDex to Present at the Zooming with LD Virtual Investor Conference

March 17, 2021

ChromaDex Corporation Reports 2020 Financial Results

March 9, 2021

ChromaDex Announces Retail Distribution of Tru Niagen® in Walmart Stores Across the United States

March 9, 2021

ChromaDex to Present at Oppenheimer 31st Annual Healthcare Conference

March 8, 2021

ChromaDex Appoints Preventative Medicine Specialist Dr. David L. Katz to its Scientific Advisory Board

March 7, 2021

ChromaDex to Report Fourth Quarter 2020 Financial Results on Wednesday, March 10, 2021

February 18, 2021

ChromaDex to Present at Benzinga’s Inaugural Small Cap Conference in December 2020

December 1, 2020

ChromaDex Announces New Clinical Trial to Investigate Niagen® and Milk Production Among Mothers in the Neonatal Intensive Care Unit (NICU)

November 16, 2020

ChromaDex and Watsons Launch New TRU NIAGEN® EX Stick Packs in Hong Kong, Expanding Product Line and Advancing Global Retail Partnership

November 8, 2020

ChromaDex Corporation Reports Third Quarter 2020 Financial Results

November 3, 2020

ChromaDex to Report Third Quarter 2020 Financial Results on Wednesday, November 4, 2020

October 27, 2020

ChromaDex Announces Study Results Showing Nutritional Protocol Including Nicotinamide Riboside Plus Standard of Care Reduces Recovery Time in COVID-19 Patients by Nearly 30%

October 5, 2020

New Preclinical Study Finds Niagen® Prevents Light-Induced Retinal Damage in Mice

September 8, 2020

ChromaDex to Present at the LD 500 Virtual Investor Conference

August 25, 2020

New Pilot Study Indicates Niagen® May Reduce Inflammatory Cytokines in Stage D Heart Failure Patients

August 17, 2020

ChromaDex to Report Second Quarter 2020 Financial Results on Thursday, August 6, 2020

July 27, 2020

ChromaDex External Research Program (CERP™) Achieves 200th Material Transfer Agreement for Niagen® (Nicotinamide Riboside) Research

July 13, 2020

ChromaDex Announces New Study Results Highlighting Promising Anti-Viral Effects of Niagen® in Coronavirus Cell Model

July 8, 2020

New Preclinical Findings Suggest Boosting NAD+ with Niagen® Holds Potential for Slowing Aging Process and Reducing Metabolic Damage

June 29, 2020

ChromaDex Research & Development Facility Earns ISO/IEC 17025: 2017 Accreditation

June 16, 2020

ChromaDex to Present at June 2020 Lytham Partners Virtual Investor Growth Conference

June 15, 2020

ChromaDex to Host Symposium on NAD+ in Human Health and Disease at NUTRITION 2020 LIVE ONLINE Annual Meeting

May 31, 2020

ChromaDex to Participate in Panel on Master Files for Dietary Supplements Hosted by the American Conference Institute (ACI) and Council for Responsible Nutrition (CRN)

May 26, 2020

ChromaDex Chief Scientific Advisor Dr. Charles Brenner Receives 2020 National Scientific Achievement Award from the American Society for Nutrition

May 20, 2020

ChromaDex Corporation Reports First Quarter 2020 Financial Results

May 10, 2020

Ninth Published Human Trial on Niagen® Nicotinamide Riboside (NR) Shows Increase in NAD+ Levels, Additional Research Highlights Downfalls of Nicotinamide Mononucleotide (NMN)

May 5, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 31 calls. Every call is listed under its year.

Decks

The 5 newest of 60 decks. Every deck is listed under its year.